



To the Copenhagen Stock Exchange
Announcement No. 23-07 / Copenhagen 26 June 2007

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

Report pursuant to the Danish Securities Trading Act, Section 28a

Copenhagen – 26 June 2007 – Pursuant to the Danish Securities Trading Act, Section 28a TopoTarget A/S (Copenhagen Stock Exchange: TOPO) is obliged to report on transactions by members of its senior management and their related parties in shares issued by TopoTarget A/S and related securities.

www.topotarget.com

Name	Peter Buhl Jensen
Reason	CEO
Issuer and ISIN code	TopoTarget A/S, DK0060086072
Transaction	Purchase
Trade date	25 June 2007
Market	Copenhagen Stock Exchange
Number	10,010
Market value in DKK	300,300

Name	Leif Hamø
Reason	CFO
Issuer and ISIN code	TopoTarget A/S, DK0060086072
Transaction	Purchase
Trade date	25 June 2007
Market	Copenhagen Stock Exchange
Number	26,677
Market value in DKK	800,310

TopoTarget A/S

For further information, please contact:

Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22

Background information

About TopoTarget

TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to www.topotarget.com.

